Episode Details

Back to Episodes
Pharmaceutical Executive Daily: Nine Companies Strike Deals for MFN Pricing

Pharmaceutical Executive Daily: Nine Companies Strike Deals for MFN Pricing

Published 2 months, 2 weeks ago
Description
The Trump administration adds nine drugmakers to its Most Favored Nation pricing program, GSK advances its dual-antigen mRNA flu vaccine into Phase III, and Simcere Zaiming licenses its tri-specific antibody Sim0660 to Roche for up to $1.53 billion.
Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us